Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging.
暂无分享,去创建一个
David F Kallmes | Kent R Thielen | Robert J McDonald | Laurence J Eckel | D. Kallmes | M. Jentoft | R. McDonald | J. McDonald | D. Murray | K. Thielen | E. Williamson | L. Eckel | Eric E Williamson | Jennifer S McDonald | Mark E Jentoft | David L Murray
[1] R R Edelman,et al. Magnetic resonance imaging (1). , 1993, The New England journal of medicine.
[2] S. Quay,et al. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. , 1991, Investigative radiology.
[3] R. Brasch,et al. Contrast-enhanced NMR imaging: animal studies using gadolinium-DTPA complex. , 1984, AJR. American journal of roentgenology.
[4] Bradley J. Erickson,et al. Functional requirements of a desktop clinical image display application , 2001, Journal of Digital Imaging.
[5] R. Lauffer,et al. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.
[6] V. Runge,et al. MRI contrast agents: Basic chemistry and safety , 2012, Journal of magnetic resonance imaging : JMRI.
[7] H. Weinmann,et al. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.
[8] P. Hauschka,et al. Incorporation of excess gadolinium into human bone from medical contrast agents. , 2009, Metallomics : integrated biometal science.
[9] Daisuke Takenaka,et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. , 2014, Radiology.
[10] S. Aime,et al. Biodistribution of gadolinium‐based contrast agents, including gadolinium deposition , 2009, Journal of magnetic resonance imaging : JMRI.
[11] P. Jungers,et al. Osmotic Nephrosis Induced by Water-Soluble Triiodinated Contrast Media in Man. A Retrospective Study of 47 Cases. , 1975, Radiology.
[12] N. Fukumitsu,et al. Imaging of Bilateral Striopallidodentate Calcinosis , 2002, Clinical nuclear medicine.
[13] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[14] P. Hals,et al. Biodistribution and toxicity of MR imaging contrast media , 1993, Journal of magnetic resonance imaging : JMRI.
[15] A. Aisen,et al. Preliminary clinical trial of gadodiamide injection: A new nonionic gadolinium contrast agent for MR imaging , 1991, Journal of magnetic resonance imaging : JMRI.
[16] S. Cowper,et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.
[17] Luca Roccatagliata,et al. Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype. , 2009, Radiology.
[18] M. Tweedle,et al. Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy , 2006, Investigative radiology.
[19] T. Grobner. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[20] Vincenzo Di Lazzaro,et al. Progressive Increase of T1 Signal Intensity of the Dentate Nucleus on Unenhanced Magnetic Resonance Images Is Associated With Cumulative Doses of Intravenously Administered Gadodiamide in Patients With Normal Renal Function, Suggesting Dechelation , 2014, Investigative radiology.
[21] U. Karst,et al. Determination of gadolinium-based MRI contrast agents in biological and environmental samples: a review. , 2013, Analytica chimica acta.
[22] H. Ellinger-Ziegelbauer,et al. The Role of Residual Gadolinium in the Induction of Nephrogenic Systemic Fibrosis-Like Skin Lesions in Rats , 2011, Investigative radiology.
[23] D. Worah,et al. Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent. , 1993, Investigative radiology.
[24] E. Holtz,et al. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. , 1993, Investigative radiology.
[25] R. Edelman,et al. Magnetic resonance imaging (2) , 1993, The New England journal of medicine.
[26] J. Gauvrit,et al. Incidence of Nephrogenic Systemic Fibrosis in Patients Undergoing Dialysis After Contrast-Enhanced Magnetic Resonance Imaging With Gadolinium-Based Contrast Agents: The Prospective Fibrose Nephrogénique Systémique Study , 2014, Investigative radiology.
[27] Shigeru Furui,et al. High Signal Intensity in Dentate Nucleus on Unenhanced T1-weighted MR Images: Association with Linear versus Macrocyclic Gadolinium Chelate Administration. , 2015, Radiology.
[28] Zhuxian Zhou,et al. Gadolinium-based contrast agents for magnetic resonance cancer imaging. , 2013, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[29] W. Cacheris,et al. The relationship between thermodynamics and the toxicity of gadolinium complexes. , 1990, Magnetic resonance imaging.